Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0W2EI
|
|||
Former ID |
DNC008893
|
|||
Drug Name |
C[Glu21-Lys26][Gly8]GLP-1(7-37)-NH2
|
|||
Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
Structure |
Download2D MOL
|
|||
Formula |
C150H225N41O45
|
|||
Canonical SMILES |
CCC(C)C(C(=O)NC(C)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCCN)C(=O)NCC(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CCC(=O)O)NC(=O)C4CCCCNC(=O)CCC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)N4)C)C)CCC(=O)N)NC(=O)C(CC(C)C)NC(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC6=CC=CC=C6)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC7=CN=CN7)N
|
|||
InChI |
1S/C150H225N41O45/c1-16-77(10)121(147(234)169-80(13)126(213)177-104(59-86-62-160-91-35-24-23-34-89(86)91)137(224)179-100(55-74(4)5)138(225)188-119(75(6)7)145(232)176-93(36-25-27-51-151)129(216)163-66-113(202)170-92(38-29-53-159-150(155)156)128(215)161-64-110(154)199)190-139(226)102(56-83-30-19-17-20-31-83)180-134(221)98(46-50-117(207)208)175-133(220)94-37-26-28-52-158-111(200)48-44-96(131(218)164-67-114(203)172-97(43-47-109(153)198)132(219)168-78(11)124(211)167-79(12)125(212)173-94)174-135(222)99(54-73(2)3)178-136(223)101(58-85-39-41-88(197)42-40-85)181-142(229)106(69-192)184-144(231)108(71-194)185-146(233)120(76(8)9)189-141(228)105(61-118(209)210)182-143(230)107(70-193)186-149(236)123(82(15)196)191-140(227)103(57-84-32-21-18-22-33-84)183-148(235)122(81(14)195)187-115(204)68-165-130(217)95(45-49-116(205)206)171-112(201)65-162-127(214)90(152)60-87-63-157-72-166-87/h17-24,30-35,39-42,62-63,72-82,90,92-108,119-123,160,192-197H,16,25-29,36-38,43-61,64-71,151-152H2,1-15H3,(H2,153,198)(H2,154,199)(H,157,166)(H,158,200)(H,161,215)(H,162,214)(H,163,216)(H,164,218)(H,165,217)(H,167,211)(H,168,219)(H,169,234)(H,170,202)(H,171,201)(H,172,203)(H,173,212)(H,174,222)(H,175,220)(H,176,232)(H,177,213)(H,178,223)(H,179,224)(H,180,221)(H,181,229)(H,182,230)(H,183,235)(H,184,231)(H,185,233)(H,186,236)(H,187,204)(H,188,225)(H,189,228)(H,190,226)(H,191,227)(H,205,206)(H,207,208)(H,209,210)(H4,155,156,159)/t77-,78-,79-,80-,81+,82+,90-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,119-,120-,121-,122-,123-/m0/s1
|
|||
InChIKey |
YLHNVPBGRUSXJQ-RHBBJNDVSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Glucagon-like peptide 1 receptor (GLP1R) | Target Info | Inhibitor | [1] |
KEGG Pathway | cAMP signaling pathway | |||
Neuroactive ligand-receptor interaction | ||||
Insulin secretion | ||||
Reactome | Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | |||
G alpha (s) signalling events | ||||
Glucagon-type ligand receptors | ||||
WikiPathways | GPCRs, Class B Secretin-like | |||
Integration of energy metabolism | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo acti... J Med Chem. 2008 May 8;51(9):2758-65. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.